We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Manati Closeout Clears Path to Nulojix Approval
BMS Manati Closeout Clears Path to Nulojix Approval
July 5, 2011
In a recent closeout letter, the FDA told Bristol-Myers Squibb (BMS) that the corrective actions BMS has taken at its Manati, Puerto Rico, facility “sufficiently addressed” concerns raised in an August 2010 warning letter, paving the way for the June 15 approval of BMS’ kidney transplant drug Nulojix.